More from Renaissance Capital

Regulus Therapeutics sets terms for $50 million IPO

By Renaissance Capital,  September 07, 2012, 04:13:43 PM EDT

Regulus Therapeutics, a biopharmaceutical company focused on developing drugs that target microRNA, announced terms for its IPO on Friday. The San Diego, CA-based company plans to raise $50 million by offering 4.5 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Regulus Therapeutics would command a market value of $239 million. Regulus Therapeutics, which was founded in 2007 and booked $14 million in sales for the 12 months ended June 30, 2012, plans to list on the NASDAQ under the symbol RGLS. Lazard Capital Markets, Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.


This article appears in: News Headlines, IPOs

Referenced Stocks:



Latest News Video

House 'Exploded in Front of Us'
House 'Exploded in Front of Us'     
An Emotional Ending to David Beckham's Soccer Career
An Emotional Ending to David Beckha...
Funeral For Female Politician Gunned Down in Pakistan
Funeral For Female Politician Gunne...


Sign-in
Existing NASDAQ.com member? Log in here.

By signing into to the site using any of the third-party services above, you agree to NASDAQ.com's Terms of Use.

From Our Trusted News Source





Most Active by Volume:

Company Last Sale Change Net / %
BAC $ 13.43 0.07  0.52%
CSCO $ 24.24 0.35  1.48%
MSFT $ 34.87 0.79  2.32%
F $ 15.08 0.44  3.01%
ARUN $ 13.10 4.51  25.61%
SIRI $ 3.50 0.05  1.45%
GE $ 23.46 0.19  0.82%
S $ 7.32 0.04  0.55%